540222 Stock Overview
Laurus Labs Limited, together with its subsidiaries, engages in the development, manufacture, and sale of medicines and active pharmaceutical ingredients (APIs) in India and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Laurus Labs Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹434.40 |
| 52 Week High | ₹470.90 |
| 52 Week Low | ₹279.65 |
| Beta | 1.14 |
| 1 Month Change | 9.05% |
| 3 Month Change | 14.75% |
| 1 Year Change | 44.78% |
| 3 Year Change | -8.44% |
| 5 Year Change | 468.66% |
| Change since IPO | 352.03% |
Recent News & Updates
Recent updates
Shareholder Returns
| 540222 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -1.9% | -0.5% | 1.4% |
| 1Y | 44.8% | 55.3% | 46.1% |
Return vs Industry: 540222 underperformed the Indian Pharmaceuticals industry which returned 55.3% over the past year.
Return vs Market: 540222 underperformed the Indian Market which returned 46.1% over the past year.
Price Volatility
| 540222 volatility | |
|---|---|
| 540222 Average Weekly Movement | 4.7% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: 540222 has not had significant price volatility in the past 3 months.
Volatility Over Time: 540222's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 5,753 | Satyanarayana Chava | www.lauruslabs.com |
Laurus Labs Limited, together with its subsidiaries, engages in the development, manufacture, and sale of medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company develops, manufactures, and sells APIs and advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C therapeutic areas. It also develops and manufactures oral solid formulations for ARVs, anti-diabetic, cardiovascular, PPIs, and central nervous system.
Laurus Labs Limited Fundamentals Summary
| 540222 fundamental statistics | |
|---|---|
| Market cap | ₹234.13b |
| Earnings (TTM) | ₹1.88b |
| Revenue (TTM) | ₹49.82b |
124.6x
P/E Ratio4.7x
P/S RatioIs 540222 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 540222 income statement (TTM) | |
|---|---|
| Revenue | ₹49.82b |
| Cost of Revenue | ₹24.90b |
| Gross Profit | ₹24.92b |
| Other Expenses | ₹23.04b |
| Earnings | ₹1.88b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 25, 2024
| Earnings per share (EPS) | 3.49 |
| Gross Margin | 50.01% |
| Net Profit Margin | 3.77% |
| Debt/Equity Ratio | 52.8% |
How did 540222 perform over the long term?
See historical performance and comparison